布基纳法索Dafra地区新生儿乙肝疫苗首剂接种的成本效果研究
该研究评估在布基纳法索Dafra地区现行三剂五联疫苗程序基础上增加新生儿乙肝疫苗首剂(HepB-BD)的成本效果。采用决策树联合马尔可夫模型分析2017年出生队列(n=11,462),结果显示增加HepB-BD可节省净成本并减少DALYs,在布基纳法索人均GDP阈值下具有成本效果。
要点
- 在Dafra地区,HepB-BD+HepB3较单独HepB3可净节省18,979美元并避免163个DALYs(未贴现)。
- 贴现后增量成本为554美元,避免31个DALYs,ICER为18美元/DALY。
- 在阈值671美元(人均GDP)下,HepB-BD+HepB3具有成本效果的概率为86.7%。
核心结论
- 在布基纳法索引入新生儿乙肝疫苗首剂可能具有成本效果。
研究设计与样本
- 采用决策树联合马尔可夫模型,评估2017年Dafra地区出生队列(n=11,462)中HepB-BD+HepB3对比单独HepB3的成本效果。
- 机构分娩率、疫苗覆盖率和接种成本来自现场收集数据,效果参数和水平传播风险来自既往非洲研究。
- 成本和健康结果按3%年贴现率贴现,并进行单因素和概率敏感性分析。
主要发现
- 未贴现时,HepB-BD+HepB3较单独HepB3净节省18,979美元并避免163个DALYs。
- 贴现后,增量成本为554美元,避免31个DALYs,ICER为18美元/DALY。
- 单因素敏感性分析中,在所有参数变化下HepB-BD+HepB3均具有成本效果(阈值671美元,即布基纳法索人均GDP)。
- 结果对每名接种新生儿HepB-BD单位成本和HBeAg阳性母亲围产期传播风险的变化非常敏感。
- 在阈值335美元和671美元下,HepB-BD+HepB3具有成本效果的概率分别为71.7%和86.7%。
临床怎么用
- 可为布基纳法索等非洲国家将新生儿乙肝疫苗首剂纳入免疫规划提供经济学依据。
局限性
- 结果对HepB-BD单位成本和HBeAg阳性母亲围产期传播风险等参数敏感,需结合本地数据谨慎外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization (WHO) recommends a first hepatitis B vaccine dose within 24 h of birth (HepB-BD) to prevent mother-to-child transmission. Evidence for this strategy's economic value in Africa is limited. We assessed the costs and cost-effectiveness of adding HepB-BD to the current three-dose pentavalent schedule (HepB3) in the Dafra district of the Hauts-Bassins Region in Burkina Faso. METHODS: Using a decision tree combined with a Markov model, we estimated the expected number of life-years (LY) and disability-adjusted life-years (DALYs) saved, incremental costs, and incremental cost-effectiveness ratios (ICER) of HepB-BD + HepB3 versus HepB3 alone in Dafra's 2017 birth cohort (n = 11,462). Institutional delivery rates, vaccine coverage, and vaccination costs from a health system perspective were estimated from field-collected data. We estimated the effectiveness of HepB-BD, age-specific transition probabilities, and horizontal transmission risks using data from previous African studies. Costs and health outcomes were discounted at an annual rate of 3%. We conducted one-way and probabilistic sensitivity analyses to assess uncertainty. RESULTS: In the base-case analysis without discounting, HepB-BD + HepB3 yielded a net cost saving of US$18,979 and saved 163 DALYs compared with HepB3 alone. With discounting, HepB-BD + HepB3 compared with HepB3 resulted in an incremental cost of US$554 and 31 DALYs averted, translating into an ICER of US$18/DALY averted. In one-way sensitivity analyses, HepB-BD + HepB3 remained cost-effective (at the cost-effectiveness threshold of US$671 i.e. the Burkina Faso per-capita gross domestic product) for all parameter changes. However, results were very sensitive to variations in HepB-BD unit cost per vaccinated neonate and perinatal transmission risk in mothers carrying the hepatitis B e antigen. The probabilities of HepB-BD + HepB3 being cost-effective were 71.7% and 86.7%, at the cost-effectiveness thresholds of US$335 and US$671, respectively. CONCLUSION: Introducing HepB-BD in Burkina Faso is likely to be cost-effective.
引用
- Gosset A, Diallo MY, Betsem E, et al. Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NéoVac Study). Vaccine. 2021. PMID: 34238606. doi:10.1016/j.vaccine.2021.06.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。